MAVENCLAD® (Cladribine Tablets)

MAVENCLAD® is indicated for the treatment of adult patients with highly active relapsing multiple sclerosis (RMS) as defined by clinical or imaging features.

The clinical program for MAVENCLAD® (Cladribine Tablets):

More than 7,000 PATIENT YEARS OF DATA

<table>
<thead>
<tr>
<th>TRIAL</th>
<th>DESIGN</th>
<th>PRIMARY OBJECTIVE</th>
<th>PATIENTS*</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLARITY1,2</td>
<td>Safety and Efficacy of Oral Cladribine in Subjects with Relapsing–Remitting MS</td>
<td>2-year, randomized, double-blind, placebo-controlled Phase III multi-center study</td>
<td>Reduction of qualifying relapse rate in subjects with RMS</td>
</tr>
<tr>
<td>CLARITY Extension</td>
<td>Extension Study to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects Who Have Previously Completed the CLARITY Trial</td>
<td>2-year, double-blind, placebo controlled Phase III multi-center study</td>
<td>Safety</td>
</tr>
<tr>
<td>ORACLE1</td>
<td>Oral Cladribine in Early Multiple Sclerosis</td>
<td>2-year, Phase III, randomized, double-blind, placebo-controlled, multi-center trial</td>
<td>Time to conversion to MS (from randomization), according to the revised McDonald criteria</td>
</tr>
<tr>
<td>PREMIERE</td>
<td>Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Oral Cladribine Clinical Trials</td>
<td>8-year observational, multi-center study</td>
<td>Safety</td>
</tr>
<tr>
<td>ONWARD</td>
<td>Oral Cladribine Add-on to Interferon-β (IFN-β) Therapy in MS Subjects With Active Disease</td>
<td>2-year, Phase IIb randomized, double-blind placebo-controlled study</td>
<td>Safety and tolerability</td>
</tr>
</tbody>
</table>

*Patients may have taken part in more than one of the depicted clinical trials

In August 2017, the European Commission (EC) granted marketing authorization for MAVENCLAD® for the treatment of relapsing forms of multiple sclerosis (RMS) in the 28 countries of the European Union (EU) in addition to Norway, Liechtenstein and Iceland.

Lymphopenia [20% to 25%] was the most commonly reported adverse event (AE) in patients treated with Cladribine Tablets. The incidence of infections was 48.3% with Cladribine Tablets and 42.5% with placebo, with 99.1% and 99.0% rated mild-to-moderate by investigators.1,2,3

RELEVANT PUBLICATIONS

Below is a list of publications that highlight data from the Cladribine Tablets clinical program.


MERCK IN MS

With more than 20 years of experience in the area of multiple sclerosis (MS), Merck Healthcare has a proud history of delivering innovative solutions in advancing MS care. This commitment drives our research and development to address specific areas of unmet medical needs.

CONTACT

Erin-Marie Beals
Head of Global Communications, Neurology and Immunology Communications
Erinmarie.beals@emdserono.com

The information contained is not intended for distribution in the USA and Canada. For use with HCPs/Media/Advocacy Representatives only.